To additionally confirm the efficacy of combining ABC294640 and PLX4032 in reducing vemurafenib resistance in BRAF mutant colon cancer, we established the second BRAF mutated colon cancer cell line HT-29r with acquired resistance to vemurafenib, as confirmed by a 6.7-fold higher IC50 value of vemurafenib in this cell line vs. parental HT-29 cells (Supplementary Table S1). This evidence concerns the gene BRAF and malignant colon neoplasm.